Table 2 The application of animal models for SARS-CoV-2
Animal models | Advantages | Drugs | NAbs | Vaccines | Innate immunity | Adaptive immunity | Long COVID | |
|---|---|---|---|---|---|---|---|---|
B cells | T cells | |||||||
Adenovirus transduced hACE2 mouse | Easily handling, small size, low cost, rapid breeding, availability of research tools | √ | √ | √ | √ | √ | √ | √ |
Transgenic mouse expressing hACE2 | √ | √ | √ | √ | √ | √ | ||
Mouse Adapted SARS-CoV-2 | √ | √ | √ | √ | √ | √ | ||
Hamster | Highly susceptible to SARS-CoV-2, natural ACE2 permissiveness and tissue distribution | √ | √ | √ | √ | √ | √ | |
Ferret | Relatively small size, highly susceptible to SARS-CoV-2, transmission via direct or indirect contact | √ | √ | √ | √ | |||
Rhesus macaque | Physiologically closest in similarity to humans, timeline of COVID19 clinical symptoms and seroconversion like humans | √ | √ | √ | √ | √ | √ | √ |
Cynomolgus macaque | √ | √ | √ | √ | √ | |||
African green monkey | √ | √ | √ | |||||
